Skip to main content

Genetron to Screen High Risk Individuals for Liver Cancer in Wuxi City

Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen TM . The initiative will administer 150,000 tests over three years in patients who are at high risk for developing liver cancer. In clinical trials, the HCCscreen has shown a 92% sensitivity and 93% selectivity. The city-wide initiative is led by Wuxi 's municipal government and administered by China 's National Cancer Center. More details.... Stock Symbol: (NSDQ: GTH) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.